Docetaxel +/- AZD6244 in Melanoma

• Research type

  Research Study

• Full title

  A double blind randomised phase 2 trial of docetaxel with or without AZD6244 in wt BRAF advanced melanoma

• IRAS ID

  54783

• Contact name

  Mark Middleton

• Sponsor organisation

  University of Oxford

• Eudract number

  2009-018153-23

• ISRCTN Number

  N/A

• Clinicaltrials.gov Identifier

  N/A

• Research summary

  This is a randomised, double-blind, placebo-controlled multi-centre study. Eighty patients (forty in each of two arms) with melanoma will be randomly assigned to receive treatment with docetaxel with placebo or docetaxel with AZD6244. To take part the patients' melanoma must not have a mutation in the BRAF gene, which can be tested on a small sample of their tumour.

• REC name

  South Central - Oxford A Research Ethics Committee

• REC reference

  10/H0604/59

• Date of REC Opinion

  30 Sep 2010

• REC opinion

  Further Information Favourable Opinion